Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alkermes Plc    ALKS   IE00B56GVS15

ALKERMES PLC

(ALKS)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Alkermes : Hagens Berman Reminds Alkermes Public Limited Company (ALKS) Investors of February 25, 2019 Lead Plaintiff Deadline, Updates Regarding FDA Decision

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 09:31am EDT

SAN FRANCISCO, Feb. 12, 2019 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors in Alkermes Public Limited Company (NASDAQ: ALKS) of the pending securities fraud class action and the February 25, 2019 Lead Plaintiff deadline.  If you purchased or otherwise acquired ALKS securities between February 17, 2017 and November 1, 2018 (the "class period") and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:

https://www.hbsslaw.com/cases/ALKS

or contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing

ALKS@hbsslaw.com.

Hagens Berman Sobol Shapiro LLP (PRNewsfoto/Hagens Berman Sobol Shapiro LLP)

The complaint alleges Defendants knew, throughout the class period, that the U.S Food and Drug Administration disagreed with Alkermes' clinical trial methodologies in connection with a New Drug Application ("NDA") for approval of a drug (ALKS 5461) intended to treat Major Depressive Disorder.

On November 1, 2018, Defendants announced the FDA advisory committee voted 21 to 2 against the approval of ALKS 5461.  Separately, the press reported Alkermes did not follow the FDA's previously-expressed guidance for the NDA.

This news drove the price of Alkermes shares down $3.09, or over 7.5% to close at $37.74 on November 2, 2018.

Most recently, on February 1, 2019, the Company and senior management announced the FDA informed them that it would not approve the ALKS 5461 NDA and requested additional clinical data to provide substantial evidence of the drug's effectiveness.

"Right now, our focus is on investors' losses and the extent to which Defendants may have misled them," said Hagens Berman partner Reed Kathrein.

Whistleblowers:  Persons with non-public information regarding Alkermes should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.  Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email ALKS@hbsslaw.com.

About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 80+ attorneys in 10 offices across the country.  The Firm represents investors, whistleblowers, workers and consumers in complex litigation.  More about the firm and its successes can be found at www.hbsslaw.com.  For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 510-725-3000

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/hagens-berman-reminds-alkermes-public-limited-company-alks-investors-of-february-25-2019-lead-plaintiff-deadline-updates-regarding-fda-decision-300793903.html

SOURCE Hagens Berman Sobol Shapiro LLP


© PRNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALKERMES PLC
04/18ALKERMES : to Host Conference Call to Discuss First Quarter 2019 Financial Resul..
PR
04/09ALKERMES : Announces Positive Topline Results From Innovative Study of ARISTADA®..
PU
04/08ALKERMES : Announces Departure of Jim Robinson
PR
04/03ALKERMES : Expands Awards Program With Focus on Advancing Research in Schizophre..
PR
04/01ALKERMES : to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension ..
PR
03/21ALKERMES : Statement on National Academies of Sciences, Engineering, and Medicin..
PU
03/05ALKERMES' : Corporate Presentation to be Webcast at the Cowen and Company 39th A..
PR
02/26ALKERMES : Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in ..
PR
02/20ALKERMES : to Present at the 8th Annual SVB Leerink Global Healthcare Conference
PR
02/19ALKERMES : and Clovis Oncology Initiate Research Collaboration to Explore Combin..
PU
More news